<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shoji K</submitter><funding>HHS | NIH | National Institute of Child Health and Human Development</funding><funding>NICHD NIH HHS</funding><funding>National Center for Child Health and Development</funding><pagination>2150-6</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4808231</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>60(4)</volume><pubmed_abstract>The Clinical and Laboratory Standards Institute (CLSI) revised cefepime (CFP) breakpoints forEnterobacteriaceaein 2014, and MICs of 4 and 8 μg/ml were reclassified as susceptible-dose dependent (SDD). Pediatric dosing to provide therapeutic concentrations against SDD organisms has not been defined. CFP pharmacokinetics (PK) data from published pediatric studies were analyzed. Population PK parameters were determined using NONMEM, and Monte Carlo simulation was performed to determine an appropriate CFP dosage regimen for SDD organisms in children. A total of 664 CFP plasma concentrations from 91 neonates, infants, and children were included in this analysis. The median patient age was 1.0 month (interquartile range [IQR], 0.2 to 11.2 months). Serum creatinine (SCR) and postmenstrual age (PM</pubmed_abstract><journal>Antimicrobial agents and chemotherapy</journal><pubmed_title>Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.</pubmed_title><pmcid>PMC4808231</pmcid><funding_grant_id>U54HD071601</funding_grant_id><funding_grant_id>U54HD071600</funding_grant_id><funding_grant_id>U54 HD071600</funding_grant_id><funding_grant_id>NCCHD27-6</funding_grant_id><funding_grant_id>U54 HD071601</funding_grant_id><pubmed_authors>Reed MD</pubmed_authors><pubmed_authors>van den Anker JN</pubmed_authors><pubmed_authors>Bradley JS</pubmed_authors><pubmed_authors>Domonoske C</pubmed_authors><pubmed_authors>Shoji K</pubmed_authors><pubmed_authors>Capparelli EV</pubmed_authors></additional><is_claimable>false</is_claimable><name>Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.</name><description>The Clinical and Laboratory Standards Institute (CLSI) revised cefepime (CFP) breakpoints forEnterobacteriaceaein 2014, and MICs of 4 and 8 μg/ml were reclassified as susceptible-dose dependent (SDD). Pediatric dosing to provide therapeutic concentrations against SDD organisms has not been defined. CFP pharmacokinetics (PK) data from published pediatric studies were analyzed. Population PK parameters were determined using NONMEM, and Monte Carlo simulation was performed to determine an appropriate CFP dosage regimen for SDD organisms in children. A total of 664 CFP plasma concentrations from 91 neonates, infants, and children were included in this analysis. The median patient age was 1.0 month (interquartile range [IQR], 0.2 to 11.2 months). Serum creatinine (SCR) and postmenstrual age (PM</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Apr</publication><modification>2025-04-19T01:25:27.5Z</modification><creation>2019-03-27T03:10:19Z</creation></dates><accession>S-EPMC4808231</accession><cross_references><pubmed>26810655</pubmed><doi>10.1128/AAC.02592-15</doi><doi>10.1128/aac.02592-15</doi></cross_references></HashMap>